Cargando…

Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor

We report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion was detected on comprehensive tumou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poon, Donald, Tan, Min Han, Khor, Damian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438717/ https://www.ncbi.nlm.nih.gov/pubmed/34511423 http://dx.doi.org/10.1136/bcr-2021-244271

Ejemplares similares

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
por: Pham, Chi, et al.
Publicado: (2023)

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium
por: Best, Sarah A., et al.
Publicado: (2018)

FGFR3-TACC3 fusion in solid tumors: mini review
por: Costa, Ricardo, et al.
Publicado: (2016)

FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma
por: Gött, Hanna, et al.
Publicado: (2022)

Precision medicine: Sustained response to erdafitinib in FGFR2 ‐mutant, multiply recurrent ameloblastoma
por: Lawson‐Michod, Katherine A., et al.
Publicado: (2022)

FGFR3–TACC3: A novel gene fusion in cervical cancer
por: Carneiro, Benedito A., et al.
Publicado: (2015)

A metabolic function of FGFR3-TACC3 gene fusions in cancer
por: Frattini, Véronique, et al.
Publicado: (2018)

FGFR3–TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle
por: Sarkar, Sourav, et al.
Publicado: (2017)

Histology-specific FGFR2 alterations and FGFR2-TACC2 fusion in mixed adenoid cystic and neuroendocrine small cell carcinoma of the uterine cervix
por: Gill, Corey M., et al.
Publicado: (2020)

Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions
por: Tamura, Ryo, et al.
Publicado: (2018)

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
por: Mata, Douglas A., et al.
Publicado: (2020)

Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion
por: Métais, Alice, et al.
Publicado: (2023)

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
por: Ballester, Leomar Y., et al.
Publicado: (2019)

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis
por: Zheng, Xinyi, et al.
Publicado: (2023)

RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine
por: Parker Kerrigan, Brittany C, et al.
Publicado: (2020)

Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib
por: Macklis, Paul, et al.
Publicado: (2020)

Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples
por: Kurobe, Masahiro, et al.
Publicado: (2016)

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
por: Sarkisian, Saro, et al.
Publicado: (2020)

Dutcher bodies in an IgA‐myeloma patient harbouring the FGFR3/IGH fusion
por: Manabe, Masahiro, et al.
Publicado: (2023)

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling
por: Nelson, Katelyn N., et al.
Publicado: (2018)

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling
por: Daly, C, et al.
Publicado: (2017)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Aberrations of TACC1 and TACC3 are associated with ovarian cancer
por: Lauffart, Brenda, et al.
Publicado: (2005)

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2017)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis
por: Lombardi, Benedetta, et al.
Publicado: (2017)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023)

Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib
por: Deutsch, Alana, et al.
Publicado: (2020)

Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
por: Meng, Xinmin, et al.
Publicado: (2022)

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
por: O’Reilly, E M, et al.
Publicado: (2019)

Erratum to: Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

FGFR2 amplification in colorectal adenocarcinoma
por: Carter, Jamal H., et al.
Publicado: (2017)

Not Your Typical Adenocarcinoma: A Case of Mesonephric Adenocarcinoma of the Cervix With Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation
por: Devarashetty, Sindhu, et al.
Publicado: (2022)

Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability
por: Wang, Clark G., et al.
Publicado: (2023)

TACC3 in personalized medicine
por: Murata, Stephen, et al.
Publicado: (2015)

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report
por: Ding, Xinjia, et al.
Publicado: (2021)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
por: Sayegh, Nicolas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ucel8hbmn0vmpfls30ks8gb4i3